Bendamustine as salvage treatment for patients with relapsed or refractory mantle cell lymphoma patients: a retrospective study of the Spanish experience

Patients with mantle cell lymphoma (MCL) have an adverse outcome after relapse. Bendamustine has demonstrated a good efficacy and toxicity profile in previously reported trials. In this study, we present a retrospective analysis of the Spanish experience in relapsed/refractory MCL treated with benda...

Full description

Saved in:
Bibliographic Details
Published in:Annals of hematology 2014-09, Vol.93 (9), p.1551-1558
Main Authors: García-Noblejas, A., Martínez Chamorro, C., Navarro Matilla, B., Da Silva Rodriguez, C., González-Lopez, T. J., Oña Navarrete, R., Ramírez Sánchez, M. J., Martínez Barranco, P., Sánchez Blanco, J. J., Nicolás, C., Pérez, R., Sánchez González, B., Ruedas López, A. M., Domingo-Domenech, E., Panizo, C., Macia, S., Fernández-Fonseca, E., Cannata-Ortiz, J., Arranz, R.
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Bendamustine Hydrochloride
Drug Resistance, Neoplasm - drug effects
Female
Hematology
Humans
Lymphoma, Mantle-Cell - drug therapy
Lymphoma, Mantle-Cell - epidemiology
Lymphoma, Mantle-Cell - pathology
Male
Medicine
Medicine & Public Health
Middle Aged
Nitrogen Mustard Compounds - therapeutic use
Oncology
Original Article
Recurrence
Retrospective Studies
Salvage Therapy
Spain - epidemiology
Treatment Failure
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Patients with mantle cell lymphoma (MCL) have an adverse outcome after relapse. Bendamustine has demonstrated a good efficacy and toxicity profile in previously reported trials. In this study, we present a retrospective analysis of the Spanish experience in relapsed/refractory MCL treated with bendamustine in combination or alone with the objective of knowing the efficacy and toxicity profile of this treatment in our current clinical practice. Fifty eight patients were registered: 67 % male with median age of 71 years, and 2 is the median number of previous lines. The most frequent bendamustine regimen was bendamustine plus rituximab (83 %). The median number of cycles was 5 (range 1–8). The overall response rate was 84 % with 53 % of complete response/unconfirmed complete response (CR/uCR). Median progression-free survival (PFS) was 16 months (95 % confidence interval (CI) 13.3–18.8), and for patients who achieved CR/uCR, it was 33 months (95 % CI 11.1–54.2). Median overall survival (OS) was 30 months (95 % CI 25.6–34.9). For PFS, only blastoid histology and not achieving CR after bendamustine had a significant negative impact on the univariate and multivariate analyses ( p  
ISSN:0939-5555
1432-0584
DOI:10.1007/s00277-014-2077-1